Literature DB >> 30772347

The Small Fatal Choroidal Melanoma Study. A Survey by the European Ophthalmic Oncology Group.

Susanna Jouhi1, Martine J Jager2, Stefan J R de Geus3, Laurence Desjardins4, Nils Andreas Eide5, Jean-Daniel Grange6, Jens Folke Kiilgaard7, Stefan Seregard8, Edoardo Midena9, Raffaele Parrozzani10, Jean-Pierre Caujolle11, Iwona Rospond-Kubiak12, Tero T Kivelä13.   

Abstract

PURPOSE: To determine the size at which choroidal melanomas can metastasize and to report the characteristics of small fatal choroidal melanomas (SFCM).
DESIGN: Retrospective case series.
METHODS: Ten ocular oncology services submitted 45 patients with a choroidal melanoma 3 mm or less in thickness and 9 mm or less in largest basal diameter (LBD), when treated, who developed metastases.
RESULTS: Median tumor thickness was 2.4 mm (range, 1.0-3.0 mm) and LBD 7.3 mm (range, 3.0-9.0 mm). Of 14 (31%) tumors that were first observed, 12 grew a median of 0.5 mm (range, 0.1-1.2 mm) in thickness and 1.0 mm (range, 0-3.0 mm) in LBD within a median of 7 months; 3 were initially smaller than 3 mm in LBD. Number of risk factors for growth and metastasis was 0 for 4% of the tumors; 60% were over 2 mm in thickness, 63% had subretinal fluid, 84% caused symptoms, 57% had orange pigment, and 92% were within 3 mm of the disc. Local recurrence occurred in 8 of 31 eyes (26%) treated conservatively. Median metastasis-free survival was 4.5 years (range, 0.8-15.7 years). Kaplan-Meier estimate of metastasis developing was 15% (95% confidence interval [CI], 7-26), 51% (95% CI, 36-64) and 85% (95% CI, 71-92) by 2, 5, and 10 years, respectively. By the time of analysis, 37 patients had died of metastasis after a median of 7 months.
CONCLUSIONS: Choroidal melanomas less than 3.0 mm in LBD are highly unlikely to metastasize. Risk factors of an SFCM are similar to those for all choroidal melanomas of similar size.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 30772347     DOI: 10.1016/j.ajo.2019.01.031

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  What's in a Name? Large Choroidal Nevus, Small Choroidal Melanoma, or Indeterminate Melanocytic Tumor.

Authors:  Arun D Singh; Hans E Grossniklaus
Journal:  Ocul Oncol Pathol       Date:  2021-06-07

2.  SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN SMALL CHOROIDAL MELANOMAS AND CHOROIDAL NEVI.

Authors:  Eugenia Custo Greig; Nora V Laver; Luisa S M Mendonca; Emily S Levine; Caroline R Baumal; Nadia K Waheed; Jay S Duker
Journal:  Retina       Date:  2021-06-01       Impact factor: 4.256

3.  Estimation of the timing of BAP1 mutation in uveal melanoma progression.

Authors:  Ogul E Uner; Thonnie Rose O See; Eszter Szalai; Hans E Grossniklaus; Gustav Stålhammar
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

4.  No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.

Authors:  Shiva Sabazade; Christina Herrspiegel; Viktor Gill; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2021-11-24       Impact factor: 4.430

5.  Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients.

Authors:  Viktor Gill; Christina Herrspiegel; Shiva Sabazade; Maria Fili; Louise Bergman; Bertil Damato; Stefan Seregard; Gustav Stålhammar
Journal:  Front Med (Lausanne)       Date:  2022-06-02

Review 6.  Can the MOLES acronym and scoring system improve the management of patients with melanocytic choroidal tumours?

Authors:  Bertil E Damato
Journal:  Eye (Lond)       Date:  2022-06-28       Impact factor: 4.456

7.  Small High-Risk Uveal Melanomas Have a Lower Mortality Rate.

Authors:  Rumana N Hussain; Sarah E Coupland; Helen Kalirai; Azzam F G Taktak; Antonio Eleuteri; Bertil E Damato; Carl Groenewald; Heinrich Heimann
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.